Research programme: STAT4 inhibitors - Amgen

Drug Profile

Research programme: STAT4 inhibitors - Amgen

Alternative Names: Interleukin-12 inhibitors research programme - Amgen; Research programme: interleukin-12 inhibitors - Amgen; STAT4 inhibitors research programme - Amgen

Latest Information Update: 27 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tularik
  • Class
  • Mechanism of Action Interleukin 12 inhibitors; STAT4 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Immunological disorders

Most Recent Events

  • 10 Mar 1999 Preclinical development for Immunological disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top